Clinical Trials Directory

Trials / Terminated

TerminatedNCT00399256

Improved Estimation of GFR by Cystatin C in Preventing Contrast Induced Nephropathy by NAC or Zn

Improved Estimation of Glomerular Filtration Rate by Serum Cystatin C in Preventing Contrast Induced Nephropathy by N-Acetylcysteine or Zinc

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
60 (planned)
Sponsor
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Background Prevention of contrast media (CM) induced nephropathy (CIN) by pharmacological prophylaxis (e.g. N-acetylcysteine; NAC) is controversially discussed. So far, in all interventional studies assessment of kidney function was based on measurements of serum creatinine although this surrogate biomarker has several limitations. We investigated the antioxidants NAC and zinc (Zn) for the prevention of CIN by monitoring concomitantly serum levels of creatinine and cystatin C.

Detailed description

In a prospective, placebo-controlled, double blind trial patients with moderate impaired kidney function receiving hypoosmolar, nonionic contrast medium were randomly assigned to an oral treatment for 2 days with 1.2g/day of NAC (n=19), for 1 day with 60mg/day of Zn (n=18) or placebo (n=17). All patients were periprocedural hydrated with 1ml/kg/h of 0.45% saline for 24h. At baseline (before hydration), prior to exposure of CM as well as 2 and 6 days after CM serum levels of creatinine and cystatin C have been measured.

Conditions

Interventions

TypeNameDescription
DRUGAcetylcysteine
DRUGZinc

Timeline

Start date
2004-03-01
Completion
2006-03-01
First posted
2006-11-14
Last updated
2007-02-01

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00399256. Inclusion in this directory is not an endorsement.